Dørum A - Search Results

1

Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer.

Michelsen TM, Tonstad S, Pripp AH, Tropé CG, Dørum A. Michelsen TM, et al. Among authors: dorum a. Int J Gynecol Cancer. 2010 Feb;20(2):233-9. doi: 10.1111/igc.0b013e3181ca5ff4. Int J Gynecol Cancer. 2010. PMID: 20169665

2

A randomised study of cisplatin versus thiotepa as induction chemotherapy in advanced ovarian carcinoma.

Dørum A, Kristensen GB, Tropé C. Dørum A, et al. Eur J Cancer. 1994;30A(10):1470-4. doi: 10.1016/0959-8049(94)00240-6. Eur J Cancer. 1994. PMID: 7833104 Clinical Trial.

3

Early detection of familial ovarian cancer.

Dørum A, Kristensen GB, Abeler VM, Tropé CG, Møller P. Dørum A, et al. Eur J Cancer. 1996 Sep;32A(10):1645-51. doi: 10.1016/0959-8049(96)00137-2. Eur J Cancer. 1996. PMID: 8983269 Clinical Trial.

4

The problem of skipped generation and subclinical disease in familial breast-ovarian cancer.

Dørum A, Abeler VM, Heimdal K, Tropé C, Møller P. Dørum A, et al. Acta Obstet Gynecol Scand. 1997 Feb;76(2):166-8. doi: 10.3109/00016349709050074. Acta Obstet Gynecol Scand. 1997. PMID: 9049291 Free article.

5

Inherited breast carcinoma--prospective findings in 1,194 women at risk.

Møller P, Maehle L, Heimdal K, Dørum A, Tretli S, Helgerud P, Quist H, Bjørndal H, Kåresen R, Nysted A, Varhaug JE, Fjøsne HE, Guleng RJ, Due J, Bøhler P, Giercksky KE, Tropé C, Kvinnsland S. Møller P, et al. Among authors: dorum a. Acta Oncol. 1996;35 Suppl 8:7-11. doi: 10.3109/02841869609098515. Acta Oncol. 1996. PMID: 9073043

6

A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing.

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ. Dørum A, et al. Eur J Cancer. 1997 Dec;33(14):2390-2. doi: 10.1016/s0959-8049(97)00328-6. Eur J Cancer. 1997. PMID: 9616287

7

Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL. Smith-Sørensen B, et al. Among authors: dorum a. Br J Cancer. 1998 Aug;78(3):375-81. doi: 10.1038/bjc.1998.502. Br J Cancer. 1998. PMID: 9703286 Free PMC article. Clinical Trial.

8

Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA.

Dørum A, Hovig E, Tropé C, Inganas M, Møller P. Dørum A, et al. Eur J Cancer. 1999 May;35(5):779-81. doi: 10.1016/s0959-8049(99)00050-7. Eur J Cancer. 1999. PMID: 10505039

9

Prospectively detected cancer in familial breast/ovarian cancer screening.

Dørum A, Heimdal K, Løvslett K, Kristensen G, Hansen LJ, Sandvei R, Schiefloe A, Hagen B, Himmelmann A, Jerve F, Shetelig K, Fjaerestad I, Tropé C, Møller P. Dørum A, et al. Acta Obstet Gynecol Scand. 1999 Nov;78(10):906-11. Acta Obstet Gynecol Scand. 1999. PMID: 10577622

10

[Screening for ovarian cancer].

Bjørge T, Dørum A, Tropé CG. Bjørge T, et al. Among authors: dorum a. Tidsskr Nor Laegeforen. 2000 May 10;120(12):1444-8. Tidsskr Nor Laegeforen. 2000. PMID: 10851943 Review. Norwegian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page